International – Contre le Covid-19, l’exécutif mise aussi sur le Paxlovid, l’antiviral de Pfizer

En cette période de vague ascendante de Covid-19 et de fêtes qui approchent, les pouvoirs publics misent sur la responsabilisation des Français, en leur...
Advice for Management of Clinical trials in relation to Coronavirus

UK – MHRA to recognize foreign regulatory approvals for medicines and medical technologies and...

Last week, Jeremy Hunt, Chancellor of the Exchequer, published his Spring Budget for the UK.  It identified life sciences and digital technologies as “high...

USA – FDA to require mail-back envelopes for unused opioids

Drugmakers will soon have to provide patients with postage-paid envelopes to send back unused opioids for safe disposal under a new requirement announced by...
MHRA Offers Grace Period for Device Manufacturers Dealing With Withdrawn Notified Bodies

UK – Guidance on qualified person responsible for pharmacovigilance (QPPV) including pharmacovigilance system master...

The following legal obligations apply to holders of UK marketing authorisations (MA). These include those that cover the whole of the UK, or are...

Canada – Notice – Implementation of ICH E19: A selective approach to safety data...

Health Canada, as an official member to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), is committed to...

Europe – EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna

EMA’s human medicines committee (CHMP) has recommended not renewing the conditional marketing authorisation for Translarna (ataluren), a medicine for treating patients with Duchenne muscular dystrophy. Translarna...